SUBSCRIBE
SUBSCRIBE

Lori Ellis

Head of Insights

Lori is the head of insights at BioSpace. She analyzes and comments on industry trends for BioSpace and clients. She creates engaging content for clients to support their marketing objectives. She has been part of an award-winning marketing team and has won a Muse Creative award, a Vega award and several Adobe awards in collaborative team projects for her audio narration work. Her experience in the television/film and audio industries benefits both BioSpace and partners through her moderation and hosting of live and virtual events. While she has covered all elements of the drug development process, her primary focuses are women’s health issues, the economic climate, and the ever-evolving impact of technology – specifically artificial intelligence – on the pharmaceutical industry.

Drug Development
AI Promises: Funding Data Literacy and Reality First
In this episode, Lori and guests discuss practical approaches regarding artificial intelligence and investor and industry confidence in its current state.
September 12, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
Future-Proofing: Inclusive and Protective Patient Strategies
In this episode, the third and final conversation of our mini-series on diversity in clinical trials, Lori and guests discuss framing strategies designed to protect DEI initiatives from legal challenges.
August 29, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
Eyes Wide Open: Gaining Patient Trust in the Face of Evolving Women’s Health Policies in State Legislations
Lori and guests address clinical trial design, which if done without careful consideration of the patient population can exclude patients from clinical trials instead of being inclusive.
August 15, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
Positioning QARA as a Market Access Function in Globalization
In this live panel discussion, speakers focused on the EU AI Act’s global regulatory implications for medical devices & QARA’s future. An executive summary is available.
August 6, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
The Benefits of a Connected Quality & Regulatory Ecosystem
In this live panel discussion, speakers navigate integrated ecosystems and the future of QARA. An executive summary is available.
August 6, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
Applying AI in Today’s Reality of QARA Processes
In this live panel discussion, speakers explore artificial intelligence in medtech and practical realities in QARA. An executive summary is available.
August 6, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
The Political Shape of the Future Clinical Trial Space
In this episode, Lori and guests discuss the pursuit of adequate representation and how clinical trials are being shaped by the legal environment they operate within.
August 1, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
Who Is Driving The Bus - Drug Developers & Healthcare Providers or AI?
This is the third episode of Denatured’s discussion on diversity, equity and inclusion. Here, our guests discuss imperatives around access and accountability.
July 18, 2024
 · 
1 min read
 · 
Lori Ellis
Lori Ellis interviews Dr. Peter Marks at DIA Global 2024
FDA
FDA CBER Director Dr. Peter Marks Discusses Industry Growth, Collaboration and Communication
The groundwork being done in 2024 is building the foundation for global collaboration in the future.
July 8, 2024
 · 
1 min read
 · 
Lori Ellis
DEI
Understanding That We Don’t Understand at a Molecular Level
This week on Denatured, Head of Insights Lori Ellis and guests discuss the implications of not addressing the DE&I data gaps for the future.
July 2, 2024
 · 
1 min read
 · 
Lori Ellis
DEI
Challenging Research Models to Improve Health Equity
This week on Denatured, Head of Insights Lori Ellis and guests discuss the persisting challenges of diversity, equity and inclusion when designing clinical trials.
June 20, 2024
 · 
1 min read
 · 
Lori Ellis
BioSpace and DIA speakers discuss CGT Combination
Drug Development
BioSpace x DIA: Navigating the Emergence of CGT Combination Products
BioSpace’s Lori Ellis discusses the risks and challenges of cell and gene therapy combination products with DIA speakers James Wabby, AbbVie and Rob Schulz, Suttons Creek, Inc.
May 22, 2024
 · 
1 min read
 · 
Lori Ellis
DEI
Where Do We Go From Here? The Future of Women’s Health
In the second episode of our series on women’s health, we discuss what may happen to future generations if women, the custodians of generational health, are not comfortable sharing complete medical histories.
April 24, 2024
 · 
1 min read
 · 
Lori Ellis
Policy
Can $12 Billion Jumpstart Women’s Health?
Federal funding and legislation spotlight women’s health opportunities and challenges.
April 8, 2024
 · 
8 min read
 · 
Lori Ellis
Policy
Will the IRA’s Focus on the Pharmaceutical Industry Hurt the World’s Healthcare System Instead of Helping Patients?
The pharmaceutical industry is facing critical attention, particularly around drug pricing and development costs. Drug development cost is about 10% of the total healthcare spend in the United States. Broader issues such as local monopolies, utilization, unit, and costs and local monopolies, politics and a fragmented payer system contribute to the increasingly high costs to patients.
March 28, 2024
 · 
1 min read
 · 
Lori Ellis
Load More